Lenvatinib
Phase 1/2Active 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hepatocellular Carcinoma Non-resectable
Conditions
Hepatocellular Carcinoma Non-resectable
Trial Timeline
Jul 10, 2024 → Apr 1, 2027
NCT ID
NCT05901194About Lenvatinib
Lenvatinib is a phase 1/2 stage product being developed by Eisai for Hepatocellular Carcinoma Non-resectable. The current trial status is active. This product is registered under clinical trial identifier NCT05901194. Target conditions include Hepatocellular Carcinoma Non-resectable.
What happened to similar drugs?
5 of 20 similar drugs in Hepatocellular Carcinoma Non-resectable were approved
Approved (5) Terminated (2) Active (14)
Hype Score Breakdown
Clinical
9
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03533361 | Pre-clinical | Completed |
| NCT02211222 | Pre-clinical | Completed |
| NCT05901194 | Phase 1/2 | Active |
| NCT06138769 | Phase 2 | Active |
| NCT05171335 | Phase 2 | Recruiting |
| NCT05103904 | Phase 2 | Recruiting |
| NCT04321954 | Phase 2 | Active |
| NCT04297254 | Approved | Completed |
| NCT04447755 | Phase 2 | Completed |
| NCT04008082 | Pre-clinical | Completed |
| NCT03506048 | Phase 2 | Terminated |
| NCT03009292 | Phase 1 | Completed |
| NCT03663114 | Pre-clinical | Completed |
| NCT02846766 | Phase 2 | Withdrawn |
| NCT03433703 | Phase 2 | Terminated |
| NCT03573960 | Approved | Completed |
| NCT03168074 | Phase 2 | UNKNOWN |
| NCT02953743 | Phase 1 | Completed |
| NCT02780310 | Phase 2 | Active |
| NCT02579616 | Phase 2 | Completed |
Competing Products
20 competing products in Hepatocellular Carcinoma Non-resectable